232 related articles for article (PubMed ID: 31703388)
1. South African Abietane Diterpenoids and Their Analogs as Potential Antimalarials: Novel Insights from Hybrid Computational Approaches.
Musyoka T; Bishop ÖT
Molecules; 2019 Nov; 24(22):. PubMed ID: 31703388
[TBL] [Abstract][Full Text] [Related]
2. Structure Based Docking and Molecular Dynamic Studies of Plasmodial Cysteine Proteases against a South African Natural Compound and its Analogs.
Musyoka TM; Kanzi AM; Lobb KA; Tastan Bishop Ö
Sci Rep; 2016 Mar; 6():23690. PubMed ID: 27030511
[TBL] [Abstract][Full Text] [Related]
3. Identification of Selective Novel Hits against
Nyamai DW; Tastan Bishop Ö
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471245
[TBL] [Abstract][Full Text] [Related]
4. Comparing sequence and structure of falcipains and human homologs at prodomain and catalytic active site for malarial peptide based inhibitor design.
Musyoka TM; Njuguna JN; Tastan Bishop Ö
Malar J; 2019 May; 18(1):159. PubMed ID: 31053072
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of plasmodial transketolases and identification of potential inhibitors: an in silico study.
Boateng RA; Tastan Bishop Ö; Musyoka TM
Malar J; 2020 Nov; 19(1):442. PubMed ID: 33256744
[TBL] [Abstract][Full Text] [Related]
6. Development of Plasmodium falciparum protease inhibitors in the past decade (2002-2012).
Pérez B; Teixeira C; Gomes JR; Gomes P
Curr Med Chem; 2013; 20(25):3049-68. PubMed ID: 23514416
[TBL] [Abstract][Full Text] [Related]
7. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
8. Analysis of non-peptidic compounds as potential malarial inhibitors against Plasmodial cysteine proteases via integrated virtual screening workflow.
Musyoka TM; Kanzi AM; Lobb KA; Tastan Bishop Ö
J Biomol Struct Dyn; 2016 Oct; 34(10):2084-101. PubMed ID: 26471975
[TBL] [Abstract][Full Text] [Related]
9. Identification of first-in-class plasmodium OTU inhibitors with potent anti-malarial activity.
Siyah P; Akgol S; Durdagi S; Kocabas F
Biochem J; 2021 Sep; 478(18):3445-3466. PubMed ID: 34486667
[TBL] [Abstract][Full Text] [Related]
10. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Thillainayagam M; Malathi K; Ramaiah S
J Biomol Struct Dyn; 2018 Nov; 36(15):3993-4009. PubMed ID: 29132266
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets.
Qidwai T
Curr Drug Targets; 2015; 16(10):1133-41. PubMed ID: 25738296
[TBL] [Abstract][Full Text] [Related]
12. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
Chaudhary M; Singh V; Anvikar AR; Sahi S
Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
[TBL] [Abstract][Full Text] [Related]
13. Characterization of amino acid variation at strategic positions in parasite and human proteases for selective inhibition of falcipains in Plasmodium falciparum.
Goh LL; Sim TS
Biochem Biophys Res Commun; 2005 Sep; 335(3):762-70. PubMed ID: 16095562
[TBL] [Abstract][Full Text] [Related]
14. Identification of new promising Plasmodium falciparum superoxide dismutase allosteric inhibitors through hierarchical pharmacophore-based virtual screening and molecular dynamics.
Araujo JSC; de Souza BC; Costa Junior DB; Oliveira LM; Santana IB; Duarte AA; Lacerda PS; Dos Santos Junior MC; Leite FHA
J Mol Model; 2018 Jul; 24(8):220. PubMed ID: 30056475
[TBL] [Abstract][Full Text] [Related]
15. In silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1).
Kumar A; Dhar SK; Subbarao N
J Mol Model; 2018 Aug; 24(9):232. PubMed ID: 30109440
[TBL] [Abstract][Full Text] [Related]
16. Identification of (4-(9H-fluoren-9-yl) piperazin-1-yl) methanone derivatives as falcipain 2 inhibitors active against Plasmodium falciparum cultures.
Hernández-González JE; Salas-Sarduy E; Hernández Ramírez LF; Pascual MJ; Álvarez DE; Pabón A; Leite VBP; Pascutti PG; Valiente PA
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2911-2923. PubMed ID: 30253205
[TBL] [Abstract][Full Text] [Related]
17. Establishing Computational Approaches Towards Identifying Malarial Allosteric Modulators: A Case Study of
Amusengeri A; Astl L; Lobb K; Verkhivker GM; Tastan Bishop Ö
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717270
[TBL] [Abstract][Full Text] [Related]
18. Multicomplex-based pharmacophore modeling in conjunction with multi-target docking and molecular dynamics simulations for the identification of
Manhas A; Lone MY; Jha PC
J Biomol Struct Dyn; 2019 Oct; 37(16):4181-4199. PubMed ID: 30648473
[No Abstract] [Full Text] [Related]
19. Computation-based virtual screening for designing novel antimalarial drugs by targeting falcipain-III: a structure-based drug designing approach.
Kesharwani RK; Singh DV; Misra K
J Vector Borne Dis; 2013; 50(2):93-102. PubMed ID: 23995310
[TBL] [Abstract][Full Text] [Related]
20. In silico study of M18 aspartyl amino peptidase (M18AAP) of Plasmodium vivax as an antimalarial drug target.
Rout S; Mahapatra RK
Bioorg Med Chem; 2019 Jun; 27(12):2553-2571. PubMed ID: 30929948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
